Published in Medical Letter on the CDC and FDA, February 5th, 2006
Multicell will rename LAX- 202 to MCT-125, and will further evaluate MCT-125 in a pivotal phase IIb/III clinical trial which is expected to begin before the end of the 2006.
Multiple sclerosis is an autoimmune disease in which immune cells attack and destroy the myelin sheath protecting neurons in the brain and spinal cord. About two million people worldwide are afflicted with MS, and an estimated 10,000 new MS cases are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.